|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-7-3
|
|
pubmed:abstractText |
Although platinum-based chemotherapy remains the cornerstone for treatment of ovarian cancer, some patients are resistant to the treatment and will therefore not benefit from the standard platinum-based chemotherapy. Preclinical and clinical data have suggested a potential use of excision repair cross-complementation group 1 enzyme (ERCC1) as a molecular predictor of clinical resistance to platinum-based chemotherapy. Excision repair cross-complementation group 1 enzyme is a key enzyme in the nucleotide excision repair pathway which is involved in the DNA repair mechanisms in tumor cells damaged by treatment with platinum agents. The primary aim of the present study was to investigate if immunohistochemical expression of ERCC1 protein was associated with resistance to standard combination carboplatin and paclitaxel chemotherapy in newly diagnosed ovarian cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1525-1438
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
820-5
|
|
pubmed:meshHeading |
pubmed-meshheading:19574766-Adenocarcinoma,
pubmed-meshheading:19574766-Adenocarcinoma, Clear Cell,
pubmed-meshheading:19574766-Adenocarcinoma, Mucinous,
pubmed-meshheading:19574766-Aged,
pubmed-meshheading:19574766-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19574766-Carboplatin,
pubmed-meshheading:19574766-Cystadenocarcinoma, Serous,
pubmed-meshheading:19574766-DNA-Binding Proteins,
pubmed-meshheading:19574766-Drug Resistance, Neoplasm,
pubmed-meshheading:19574766-Endometrial Neoplasms,
pubmed-meshheading:19574766-Endonucleases,
pubmed-meshheading:19574766-Female,
pubmed-meshheading:19574766-Humans,
pubmed-meshheading:19574766-Immunoenzyme Techniques,
pubmed-meshheading:19574766-Middle Aged,
pubmed-meshheading:19574766-Ovarian Neoplasms,
pubmed-meshheading:19574766-Paclitaxel,
pubmed-meshheading:19574766-Prognosis,
pubmed-meshheading:19574766-Survival Rate,
pubmed-meshheading:19574766-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
|
|
pubmed:affiliation |
Department of Oncology, Vejle Hospital, Vejle, Denmark. Karina.Dahl.Steffensen@slb.regionsyddanmark.dk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
